| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/17425255.2015.1043265 |
| P698 | PubMed publication ID | 26027878 |
| P50 | author | Carlo Baraldi | Q39803352 |
| Anna Ferrari | Q39803399 | ||
| P2093 | author name string | Emilio Sternieri | |
| P2860 | cites work | Prevalence of frequent headache in a population sample | Q46159664 |
| Caffeine and headaches | Q46485293 | ||
| Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol | Q46498393 | ||
| Modulation of central sensitisation by detoxification in MOH: results of a 12-month detoxification study | Q46534534 | ||
| Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine | Q46837623 | ||
| Effect of voriconazole on the pharmacokinetics of diclofenac | Q46885397 | ||
| Estrogen-withdrawal migraine. I. Duration of exposure required and attempted prophylaxis by premenstrual estrogen administration | Q46967136 | ||
| Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project). | Q47945935 | ||
| Medication use in patients with migraine and medication-overuse headache: the role of problem-solving and attitudes about pain medication. | Q49069176 | ||
| Prevalence of chronic headache with and without medication overuse: associations with socioeconomic position and physical and mental health status. | Q50633200 | ||
| Reduced valproic acid serum concentrations due to drug interactions with carbapenem antibiotics: overview of 6 cases. | Q50916395 | ||
| Reversible cerebral vasoconstriction syndrome following indomethacin. | Q51147122 | ||
| Psychoactivity and abuse potential of sumatriptan | Q51147391 | ||
| Short-term use of serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding. | Q51204427 | ||
| Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. | Q51703728 | ||
| Efficacy of multidisciplinary treatment in a tertiary referral headache centre. | Q51831149 | ||
| Psychiatric comorbidity in the evolution from migraine to medication overuse headache. | Q51929052 | ||
| Need for analgesics/drugs of abuse: a comparison between headache patients and addicts by the Leeds Dependence Questionnaire (LDQ). | Q52856790 | ||
| Headache attributed to a substance or its withdrawal | Q53168482 | ||
| Features of medication overuse headache following overuse of different acute headache drugs. | Q53308175 | ||
| Migraine in the United States: epidemiology and patterns of health care use. | Q53316530 | ||
| The metabolism of zolmitriptan: effects of an inducer and an inhibitor of cytochrome p450 on its pharmacokinetics in healthy volunteers. | Q53544636 | ||
| The Serotonin Syndrome | Q55871784 | ||
| Adverse reactions related to drugs for headache treatment: clinical impact | Q58896365 | ||
| Withdrawing Benzodiazepines in Primary Care | Q22305817 | ||
| Butalbital in the treatment of headache: history, pharmacology, and efficacy | Q28192576 | ||
| Herbal medication: potential for adverse interactions with analgesic drugs | Q28194408 | ||
| Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer | Q28194611 | ||
| Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study | Q28294827 | ||
| Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist: differential effects of propranolol, nadolol and metoprolol | Q28343860 | ||
| The International Classification of Headache Disorders, 3rd edition (beta version) | Q29392338 | ||
| Italian guidelines for primary headaches: 2012 revised version | Q30466790 | ||
| Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study | Q30540714 | ||
| The effect of quinidine on the analgesic effect of codeine | Q33225623 | ||
| Medication-overuse headache: epidemiology, diagnosis and treatment | Q33949551 | ||
| Risk of development of medication overuse headache with nonsteroidal anti-inflammatory drug therapy for migraine: a critically appraised topic | Q34006894 | ||
| The serotonin syndrome | Q34021904 | ||
| Drug induced refractory headache--clinical features and management | Q34032498 | ||
| Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy | Q34127399 | ||
| Ergotamine and dihydroergotamine: history, pharmacology, and efficacy | Q34173953 | ||
| Oral phenobarbital loading: a safe and effective method of withdrawing patients with headache from butalbital compounds | Q34225357 | ||
| Medication-overuse headache and opioid-induced hyperalgesia: A review of mechanisms, a neuroimmune hypothesis and a novel approach to treatment | Q34311105 | ||
| A rational approach to the management of chronic migraine | Q34321114 | ||
| The role of headache chronicity among predictors contributing to quality of life in patients with migraine: a hospital-based study. | Q34326062 | ||
| Pearls and pitfalls: neurostimulation in headache | Q34344509 | ||
| Inhibition of caffeine metabolism by ciprofloxacin in children with cystic fibrosis as measured by the caffeine breath test | Q34346755 | ||
| Drug-Induced Long QT Syndrome | Q34358104 | ||
| Interaction between digoxin and indomethacin or ibuprofen | Q34358311 | ||
| Medication overuse headache: history, features, prevention and management strategies | Q34362586 | ||
| Medication overuse headache (MOH) is a biobehavioural disorder | Q34426304 | ||
| Refractory chronic migraine: a consensus statement on clinical definition from the European Headache Federation | Q34544375 | ||
| The effect of daily caffeine use on cerebral blood flow: How much caffeine can we tolerate? | Q34604598 | ||
| Excessive acute migraine medication use and migraine progression | Q34887527 | ||
| Global prevalence of chronic migraine: a systematic review | Q34992795 | ||
| Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors | Q34996940 | ||
| Review article: metoclopramide and tardive dyskinesia | Q35011095 | ||
| Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine | Q35106611 | ||
| The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers | Q36053563 | ||
| Medication overuse headache: a critical review of end points in recent follow-up studies | Q36261109 | ||
| Factors related to seizure in tramadol poisoning and its blood concentration | Q36548909 | ||
| Behavioral facilitation of medical treatment for headache--part I: Review of headache treatment compliance | Q36623161 | ||
| Evidence-based understanding of medication-overuse headache: clinical implications | Q36641577 | ||
| Advice alone versus structured detoxification programmes for complicated medication overuse headache (MOH): a prospective, randomized, open-label trial | Q36749549 | ||
| Cephalalgiaphobia as a feature of high-frequency migraine: a pilot study | Q36940443 | ||
| Risk factors for headache chronification | Q37053918 | ||
| History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward | Q37155841 | ||
| Elimination of menstrual-related migraine beneficially impacts chronification and medication overuse | Q37280006 | ||
| Tracing transformation: chronic migraine classification, progression, and epidemiology | Q37384074 | ||
| Comprehensive inpatient treatment of refractory chronic daily headache | Q37401856 | ||
| Behavioral medicine for migraine and medication overuse headache | Q37490276 | ||
| Overuse of acute migraine medications and migraine chronification | Q37544942 | ||
| Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis | Q44341591 | ||
| Adherence to oral migraine-preventive medications among patients with chronic migraine | Q44377365 | ||
| Interaction between ketoconazole and almotriptan in healthy volunteers | Q44424388 | ||
| Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein | Q44483226 | ||
| Headache treatment before and after the consultation of a specialized centre: a pharmacoepidemiology study. | Q44850904 | ||
| Transformed migraine and medication overuse in a tertiary headache centre--clinical characteristics and treatment outcomes | Q44904189 | ||
| Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin | Q44996790 | ||
| Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study | Q45395151 | ||
| Drug-related admissions due to interaction with an old drug, lithium | Q45790337 | ||
| Clinical impact of drug-drug interaction between aspirin and prednisolone at a cancer center. | Q45936595 | ||
| Chronic daily headache with medication overuse: predictors of outcome 1 year after withdrawal therapy | Q46112645 | ||
| Occipital nerve blocks: effect of symptomatic medication: overuse and headache type on failure rate | Q37632509 | ||
| Clinical features, pathophysiology, and treatment of medication-overuse headache | Q37714079 | ||
| The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper | Q37771430 | ||
| A practice guide for continuous opioid therapy for refractory daily headache: patient selection, physician requirements, and treatment monitoring | Q37774698 | ||
| What is the Role of Dependence‐Related Behavior in Medication‐Overuse Headache? | Q37784245 | ||
| Treatment of Chronic Migraine | Q37809775 | ||
| Pathophysiology of medication overuse headache: insights and hypotheses from preclinical studies | Q37858847 | ||
| Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. | Q37861402 | ||
| Persistent medication-induced neural adaptations, descending facilitation, and medication overuse headache. | Q37862036 | ||
| Dependent behavior in patients with medication-overuse headache | Q37962457 | ||
| Refractory migraine - a review | Q38081178 | ||
| Closing remarks: what future prospects can we expect in migraine management? | Q38108476 | ||
| OnabotulinumtoxinA for the treatment of headache | Q38136258 | ||
| Choosing wisely in headache medicine: the American Headache Society's list of five things physicians and patients should question | Q38165189 | ||
| CAM in the real world: you may practice evidence-based medicine, but your patients don't | Q38207138 | ||
| Diagnosis, pathophysiology and management of chronic migraine: a proposal of the Belgian Headache Society. | Q38223491 | ||
| Menstrual migraine: an updated review on hormonal causes, prophylaxis and treatment | Q38237616 | ||
| Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants | Q38246706 | ||
| Risk factors of chronic daily headache or chronic migraine | Q38270464 | ||
| Acetaminophen hepatotoxicity: an updated review | Q38299336 | ||
| Critical issues on opioids in chronic non-cancer pain: an epidemiological study | Q39348642 | ||
| Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells | Q39359313 | ||
| Analgesic rebound headache | Q39564441 | ||
| Amelioration of ergotamine withdrawal symptoms with naproxen | Q42212562 | ||
| Acute kidney injury caused by tenofovir disoproxil fumarate and diclofenac co-administration | Q42249736 | ||
| The use of methylergonovine (Methergine) in the initial control of drug induced refractory headache | Q42288612 | ||
| Refractory chronic migraine: long-term follow-up using a refractory rating scale | Q42568377 | ||
| Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics | Q42633478 | ||
| Predicting the probability of relapse after discontinuation of migraine preventive treatment with topiramate | Q42870243 | ||
| The role of prevention | Q42917916 | ||
| Cortical hyperexcitability and mechanism of medication-overuse headache | Q42936120 | ||
| Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan | Q42949209 | ||
| Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir | Q43065950 | ||
| Sodium valproate acutely inhibits lamotrigine metabolism | Q43224428 | ||
| Clinical features of withdrawal headache following overuse of triptans and other headache drugs | Q43797818 | ||
| Does chronic daily headache arise de novo in association with regular use of analgesics? | Q44326422 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| P304 | page(s) | 1127-1144 | |
| P577 | publication date | 2015-05-31 | |
| P1433 | published in | Expert Opinion on Drug Metabolism & Toxicology | Q5421205 |
| P1476 | title | Medication overuse and chronic migraine: a critical review according to clinical pharmacology | |
| P478 | volume | 11 |
| Q40185150 | An ecological study of the extent and factors associated with the use of prescription and over-the-counter codeine in Australia |
| Q93018107 | Current and emerging evidence-based treatment options in chronic migraine: a narrative review |
| Q94460429 | From transformation to chronification of migraine: pathophysiological and clinical aspects |
| Q37166083 | Hair analysis for detection of triptans occasionally used or overused by migraine patients-a pilot study |
| Q90704102 | Intra-patient variability of the hair levels of pain medications in chronic migraine patients - a pilot study |
| Q37624770 | Mindfulness and pharmacological prophylaxis after withdrawal from medication overuse in patients with Chronic Migraine: an effectiveness trial with a one-year follow-up |
| Q38913928 | Single-blind, randomized, pilot study combining shiatsu and amitriptyline in refractory primary headaches |
Search more.